TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31141514

Group type: EXPERIMENTAL
Intervention: HIV testing at health centers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV testing at referral hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient care at referral and provincial hospitals
Number of subjects: 0
Study: 28937065

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (i.v. CyP)
Number of subjects: 40
Study: 25346067

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24621999

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21355150

Group type: EXPERIMENTAL
Intervention: Acupoint-catgut-embedding therapy combined with conventional western medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional western medication
Number of subjects: 60
Study: 19819660

Group type: EXPERIMENTAL
Intervention: Consultation skills training (CST) program
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 375
Study: 16879517

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg x kg(‐1) iv
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12762871

Group type: EXPERIMENTAL
Intervention: Chronic electrical capsular stimulation (stimulation-on condition)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Postoperative stimulator-off condition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chronic electrical capsular stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Preoperative PET scans vs. 3 months of stimulation
Number of subjects: 6
Study: 11404138

Group type: EXPERIMENTAL
Intervention: Group I (SKT without opening pleurae)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Group II (pedunculated technique with open pleurae)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Group III (SKT with incidentally opened pleurae)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 299

Group type: COMPARATOR
Intervention: Group II
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Group III
Number of subjects: 299
Study: 9236572

Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 101

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 101
Study: 7658972

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered at 25 U/kg/dose, i.v. route, three times weekly, adjusted according to hematimetric response.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) treatment.
Number of subjects: 18
Study: 3300135

Group type: EXPERIMENTAL
Intervention: PGE2 gel, 0.5 mg (2.5 ml)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Non-gel control
Number of subjects: 416
Study: 31045610

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention applied during hemodialysis, with 12 applications over 1 month.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard care (control group) during hemodialysis.
Number of subjects: 186
Study: 28111095

Group type: EXPERIMENTAL
Intervention: School-based intervention focused on training teachers, providing opportunities for physical activity in the school environment, and health education over four months.
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 1085
Study: 25449207

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase ≤143 U/l
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Bone-specific alkaline phosphatase (BSAP) <146 U/l
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Corrected urinary N-telopeptide (uNTx) ≤50 nmol/mmol
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Mild or no pain (BPI-SF score ≤4)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: No previous skeletal-related event (SRE)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Longer time from initial diagnosis to first bone metastasis
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Longer time from first bone metastasis to randomization
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) level <10 ng/ml
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Hemoglobin >128g/l
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Absence of visceral metastases
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Eastern Cooperative Oncology Group (ECOG) score ≤1
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1901
Study: 22759078

Group type: EXPERIMENTAL
Intervention: OZ439 (50-1200 mg as capsule; 400-1600 mg as oral dispersion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OZ439 (200-800 mg/day for 3 days as oral dispersion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OZ439
Number of subjects: 0
Study: 21724705

Group type: EXPERIMENTAL
Intervention: CH-1504 (0.25 mg, 0.5 mg, or 1.0 mg once-daily oral doses)
Number of subjects: 201

Group type: COMPARATOR
Intervention: MTX (titrated to 20.0 mg once-weekly oral doses)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CH-1504
Number of subjects: 201

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 201
Study: 18095967

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg.kg(‐1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 84
Study: 16522392

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g calcium/d)
Number of subjects: 8325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8325
Study: 12673721

Group type: EXPERIMENTAL
Intervention: 2-cm margin
Number of subjects: 326

Group type: COMPARATOR
Intervention: 5-cm margin
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Isoprinosine (adjuvant treatment)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Observation (control for Isoprinosine)
Number of subjects: 326
Study: 10903017

Group type: EXPERIMENTAL
Intervention: Esmolol (15 mg/min) added to cold blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 40
Study: 9021698

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) after high dose therapy
Number of subjects: 44
Study: 8256950

Group type: EXPERIMENTAL
Intervention: Lactose-free formula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactose containing formula
Number of subjects: 60
Study: 3899398

Group type: EXPERIMENTAL
Intervention: Fansimef (750 mg mefloquine, 1500 mg sulfadoxine, 75 mg pyrimethamine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (Fansidar)
Number of subjects: 20
Study: 30947642

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 28985286

Group type: EXPERIMENTAL
Intervention: Organizational-support strategies (e.g. manager support, emails) with activity tracker
Number of subjects: 153

Group type: COMPARATOR
Intervention: Organizational-support strategies (e.g. manager support, emails) without activity tracker
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Organizational-support strategies (with or without activity tracker)
Number of subjects: 153
Study: 25891131

Group type: EXPERIMENTAL
Intervention: EP-RPDs
Number of subjects: 54

Group type: COMPARATOR
Intervention: C-RPDs
Number of subjects: 54
Study: 24315492

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection + thumb spica cast (CSI + TSC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 67
Study: 22673486

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) 200 units (Dysport)
Number of subjects: 40
Study: 20479569

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 6 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Discontinuation of growth hormone therapy for 12 months
Number of subjects: 6
Study: 18362722

Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Haas expander
Number of subjects: 40
Study: 15994622

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (25-mug daily dose of ethinyl estradiol)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Contraceptive vaginal ring (15-mug daily dose of ethinyl estradiol)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Contraceptive vaginal ring
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 201
Study: 12622108

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (group B) using propofol and remifentanil infusions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balanced anaesthesia (group A) using fentanyl, propofol and isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (group B)
Number of subjects: 100
Study: 10589958

Group type: EXPERIMENTAL
Intervention: Biopsy findings with evidence of fibrosis, tubular atrophy, or CD3gamma transcription
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cytokine transcripts and histological evidence of injury
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Degree of lymphocytic infiltrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intrigraft CD3y transcription
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IL-6 and IL-8 transcripts
Number of subjects: 40
Study: 8735328

Group type: EXPERIMENTAL
Intervention: Informational audiotapes
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 8102305

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SASP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 2423788

Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indoramin 0.2 mg/kg i.v.
Number of subjects: 15
Study: 30546229

Group type: EXPERIMENTAL
Intervention: Experimental A group (conventional, noninvasive treatment with raj‐yoga meditation therapy and pranayama)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (conventional, noninvasive treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental B group (Raj‐yoga meditation therapy and pranayama only)
Number of subjects: 30
Study: 27776506

Group type: EXPERIMENTAL
Intervention: Multi-component workplace health promotion (WHP) intervention including intelligent physical exercise training (IPET), dietary advice and weight loss (DAW), and cognitive behavioural training (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component workplace health promotion (WHP) intervention
Number of subjects: 0
Study: 25359348

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once daily
Number of subjects: 581

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 581
Study: 22407003

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% ointment
Number of subjects: 30
Study: 22046746

Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total removal of wisdom teeth
Number of subjects: 0
Study: 18268285

Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: pegfilgrastim 12 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: filgrastim 5 mug/kg/day
Number of subjects: 90
Study: 16502351

Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12391130

Group type: EXPERIMENTAL
Intervention: Maximum strength (MS) resistance exercise protocol: 4 sets x 5 reps at 88% of 1 RM with 3 min rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Muscular hypertrophy (MH) resistance exercise protocol: 4 sets x 10 reps at 75% of 1 RM with 2 min rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) resistance exercise protocol: 4 sets x 15 reps at 60% of 1 RM with 1 min rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (C) session
Number of subjects: 10
Study: 10440212

Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha regimen 1 (780 million units over 6 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha regimen 2 (840 million units over 6 months)
Number of subjects: 44
Study: 7927247

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor therapy
Number of subjects: 9
Study: 2595643

Group type: EXPERIMENTAL
Intervention: Maprotiline 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maprotiline 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maprotiline 75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1103916

Group type: EXPERIMENTAL
Intervention: Oral administration of diazepam 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular administration into the deltoid muscle of diazepam 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular administration into the vastus lateralis muscle of diazepam 10 mg
Number of subjects: 8
Study: 31577085

Group type: EXPERIMENTAL
Intervention: 2 g intravenous vitamin C
Number of subjects: 101

Group type: COMPARATOR
Intervention: 100 mg aceclofenac
Number of subjects: 101
Study: 28485987

Group type: EXPERIMENTAL
Intervention: Gate questions
Number of subjects: 1048

Group type: COMPARATOR
Intervention: No gate questions
Number of subjects: 1048
Study: 25948717

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LVT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 121
Study: 23332020

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention targeting reducing smoking initiation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Increasing homework (control group)
Number of subjects: 36
Study: 21575187

Group type: EXPERIMENTAL
Intervention: DOTS treatment for TB patients
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: Body weight at initiation of anti-TB treatment (<35 kg)
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: Patient category
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: Year of enrollment
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: Treatment center
Number of subjects: 6450
Study: 17990218

Group type: EXPERIMENTAL
Intervention: Single carbohydrate feeding (SF) - 2.5 g carbohydrate per kg body mass, 3 hours before exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Multiple carbohydrate feedings (MF) - 2.5 g carbohydrate per kg body mass in 5 equal doses at 3, 2.5, 2, 1.5, and 1 hour before exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P) - liquid placebo 3 hours before exercise
Number of subjects: 8
Study: 17048976

Group type: EXPERIMENTAL
Intervention: Aliskiren 300mg
Number of subjects: 60
Study: 12973962

Group type: EXPERIMENTAL
Intervention: Odds Ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative Risk
Number of subjects: 0
Study: 11009490

Group type: EXPERIMENTAL
Intervention: 8-week exercise program (excluding forearm exercise)
Number of subjects: 12
Study: 9301390

Group type: EXPERIMENTAL
Intervention: Intradermal testing
Number of subjects: 212

Group type: COMPARATOR
Intervention: Prick testing
Number of subjects: 212
Study: 7957157

Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at -7 degrees C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at 0 degrees C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at +7 degrees C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact pressure at 0.1 N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact pressure at 5.9 N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact pressure at 9.8 N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Large contact material mass (3559 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Small contact material mass (108 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole body thermal balance
Number of subjects: 20
Study: 3112038

Group type: EXPERIMENTAL
Intervention: 10% maltose solution at 0.2 g/kg/h
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10% maltose solution at 0.4 g/kg/h
Number of subjects: 2
Study: 28991513

Group type: EXPERIMENTAL
Intervention: Dabrafenib (D) + Trametinib (T) 150/2
Number of subjects: 99

Group type: COMPARATOR
Intervention: Dabrafenib (D) monotherapy
Number of subjects: 99
Study: 28525977

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) target of <140 mmHg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) target of <180 mmHg
Number of subjects: 270
Study: 25899785

Group type: EXPERIMENTAL
Intervention: Dacomitinib (30-45 mg daily in 28-day cycles)
Number of subjects: 30
Study: 23810939

Group type: EXPERIMENTAL
Intervention: Stop Light Diet enhanced with reduced energy/fat pre-packaged meals (eSLD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Recommended care reduced energy/fat meal plan diet (RC)
Number of subjects: 150
Study: 22010238

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 6% glycerin
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Crude glycerin samples with high levels of fatty acids (24% and 35%)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: All glycerin samples
Number of subjects: 864

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 864
Study: 18185038

Group type: EXPERIMENTAL
Intervention: Test group (ankle assigned for testing)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Validation group (ankle assigned for validation)
Number of subjects: 115
Study: 17010744

Group type: EXPERIMENTAL
Intervention: Clobetasol foam plus calcipotriene ointment (twice-daily for 2 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Calcipotriene (monotherapy for 2 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clobetasol foam (monotherapy for 2 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Weekday calcipotriene plus weekend pulse clobetasol foam (6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Vehicle (6 months)
Number of subjects: 86
Study: 14700173

Group type: EXPERIMENTAL
Intervention: Delayed surgery with pre-operative stabilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 0
Study: 10918802

Group type: EXPERIMENTAL
Intervention: QUOROM statement checklist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QUOROM statement flow diagram
Number of subjects: 0
Study: 8861665

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 800 mg and 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU)
Number of subjects: 10
Study: 1297939

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg once daily for seven days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg once daily for seven days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both Zopiclone and Midazolam
Number of subjects: 88
Study: 6925461

Group type: EXPERIMENTAL
Intervention: C 1821, administered orally for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered orally for 14 days
Number of subjects: 0
Study: 31303022

Group type: COMPARATOR
Intervention: Flat postoperative shoes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reverse camber postoperative shoes
Number of subjects: 100
Study: 29436087

Group type: EXPERIMENTAL
Intervention: Multidirectional reach training combined with conventional physical therapy (30 min each, 3 days a week for 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional physical therapy (30 min per day, 3 days a week for 4 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multidirectional reach training combined with conventional physical therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 16
Study: 27149954

Group type: EXPERIMENTAL
Intervention: Home-based self-management standing programme with advice and support along with usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based self-management standing programme
Number of subjects: 0
Study: 24012203

Group type: EXPERIMENTAL
Intervention: Continuous norepinephrine administration starting with 2 μg/kg per hour combined with 1 ml/kg per hour of Ringer's maleate solution until bladder removal, then 3 ml/kg per hour of Ringer's maleate solution (norepinephrine/low‐volume group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group receiving 6 ml/kg per hour of Ringer's maleate solution throughout surgery
Number of subjects: 166
Study: 21660978

Group type: EXPERIMENTAL
Intervention: 100 mg danoprevir solution delivered to the distal small bowel and colon via an Enterion™ capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg danoprevir powder to the colon via an Enterion™ capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg danoprevir IR soft gel capsule
Number of subjects: 0
Study: 19300424

Group type: EXPERIMENTAL
Intervention: Oscillometric device (automated monitors)
Number of subjects: 3355

Group type: COMPARATOR
Intervention: Usual care (mercury or aneroid sphygmomanometers)
Number of subjects: 3355
Study: 16532880

Group type: EXPERIMENTAL
Intervention: Specialty approach (medication restricted to smoking cessation clinics)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Primary care approach (most smokers treated by the primary care provider)
Number of subjects: 40
Study: 15567788

Group type: EXPERIMENTAL
Intervention: Intravenous propofol combined with fentanyl (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous propofol (group A)
Number of subjects: 100
Study: 10786107

Group type: EXPERIMENTAL
Intervention: Subcutaneous suture (group 1)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No subcutaneous suture (group 2)
Number of subjects: 146